• VeriStrat® Outcomes Data in Lung Cancer to be Presented at IASLC/ESMO 2nd European Lung Cancer Conference

    April 19, 2010 Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone, M.D., Ph.D., Professor of Medicine and Cancer Biology, Vanderbilt University School of Medicine, on Friday, April 30th at the 2nd European Lung Cancer Conference to be held in Geneva. The purpose of the ... Read more
  • Biodesix CEO to Present at Personalized Medicine Partnerships Conference

    February 5, 2010 Biodesix, Inc. announces that David Brunel, Chief Executive Officer, will present at the 2010 Personalized Medicine Partnerships Conference, Wednesday, February 24th, at 11:00 a.m. eastern time. The conference takes place February 22-24th at the Doubletree Hotel in Philadelphia, PA, and will include presentations by both diagnostic and pharmaceutical companies. Mr. Brunel will provide an overview ... Read more
  • Biodesix Secures $10 Million in Series B-1 Funding

    September 28, 2009 Funding to further the commercialization of VeriStrat® Biodesix, Inc., a privately held molecular diagnostics company focused on proteomic-based diagnostics discovery and commercialization, announced today that it has completed the initial tranche of its $10 million Series B-1 financing round. The financing was led by existing shareholders and members of the Board of Directors. “We are excited with ... Read more
  • Biodesix Announces VeriStrat® Data in Head and Neck Cancer to be Presented at ASCO

    May 14, 2009 Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on Monday, June 1st at the 45th Annual Meeting of ... Read more
  • Biodesix Advances the Field of Personalized Medicine with the Launch of VeriStrat®

    May 5, 2009 Test will help oncologists guide treatment of patients with non-small cell lung cancer Biodesix, Inc. today announces U.S. commercial availability of VeriStrat, a unique, blood-based, proteomic test for patients with advanced stage non-small cell lung cancer (NSCLC). VeriStrat identifies patients who are likely to have good or poor outcomes following treatment with epidermal growth factor receptor ... Read more
  • Biodesix Names Paul J Beresford, Formerly of Roche Diagnostics, as Vice President, Business Development and Stategic Marketing

    December 5, 2008 Biodesix, Inc, announced today that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Dr. Beresford will help drive all business development activities including the establishment of relationships with pharmaceutical and biotechnology to identify and develop ... Read more
  • Biodesix Announces Receipt of CLIA Registration Number

    October 31, 2008 Biodesix, Inc. (the “Company”), is pleased to announce receipt of a CLIA registration number 06D1090464 which allows the Company to commercially market VeriStrat®, the serum molecular diagnostic test described in the Journal of the National Cancer Institute 2007 99(11):838-846. The Company is making VeriStrat® available to qualified physicians in locations where the product is compliant with ... Read more
  • Biodesix Names Douglas E. Swan, formerly of Imclone Systems Incorporated, as Vice President, Commercial Operations

    October 1, 2008 Biodesix, Inc, announced today that Douglas E. Swan has joined the Company as Vice President, Commercial Operations, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Mr. Swan will be responsible for all commercial functions related to the marketing and sales of VeriStrat®. VeriStrat represents the company’s first diagnostic test which ... Read more